News & Updates
Showing Multidisciplinary articles
Showing
Dapagliflozin in COVID-19: Outcomes consistent regardless of kidney status
Secondary analysis of the DARE-19* trial presented at ASN Kidney Week 2021 has shown that the effect of dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 is consistent regardless of kidney disease status.
Dapagliflozin in COVID-19: Outcomes consistent regardless of kidney status
17 Nov 2021
Bleeding common after acute coronary syndrome
Acute coronary syndrome often leads to bleeding events, particularly at gastrointestinal sites, a recent study has found. Such complications are more likely to occur among older patients and those with hypertension, heart failure, and low baseline haemoglobin levels.
Bleeding common after acute coronary syndrome
17 Nov 2021
Long-term TAF works against resistant HBV, poses no excess cardiovascular risk
Tenofovir alafenamide (TAF) shows sustained safety and efficacy in heavily pretreated patients with multidrug-resistant hepatitis B virus (HBV) through 3 years of treatment, albeit leading to elevations in cholesterol levels.
Long-term TAF works against resistant HBV, poses no excess cardiovascular risk
17 Nov 2021
Statins reduce hepatocellular carcinoma risk in cirrhotic patients
The risk of hepatocellular carcinoma (HCC) among patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis is low, reveals a recent study. In addition, dose-dependent statin can substantially lower the risk of HCC in patients with NASH cirrhosis.